title: Utilisation of the ESMO-MCBS in practice of HTA.
authors: Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria claudia.wild@hta.lbg.ac.at.
authors: C
authors: C
authors: Wild
authors: Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
authors: N
authors: N
authors: Grössmann
authors: Independent Pharmaceutical Consultant, Mellieha, Malta.
authors: P V
authors: PV
authors: Bonanno
authors: Department of Finance, University of Vienna, Austria.
authors: A
authors: A
authors: Bucsics
authors: Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia.
authors: J
authors: J
authors: Furst
authors: Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania.
authors: K
authors: K
authors: Garuoliene
authors: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.|Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
authors: B
authors: B
authors: Godman
authors: Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University and State Medicines Control Agency, Vilnius, Lithuania.
authors: J
authors: J
authors: Gulbinovič
authors: Healthcare Improvement Scotland, Scottish Medicine Consortium, Glasgow, UK.
authors: J
authors: J
authors: Jones
authors: Agency for Health Technology Assessment and Tariff System, Warsaw, Poland.
authors: M K
authors: MK
authors: Pomorski
authors: Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
authors: R
authors: R
authors: Emprechtinger
mesh_terms: D006801:Humans; D008495:Medical Oncology; D013673:Technology Assessment, Biomedical